Clinical trial
12- Week Open Label Treatment of Refractory Bipolar Depression
NCT00223496 · The University of Texas Health Science Center at San Antonio, Other · Completed
Key facts
| NCT number | NCT00223496 |
|---|---|
| Title | 12- Week Open Label Treatment of Refractory Bipolar Depression |
| Official title | 12- Week Open Label Treatment of Refractory Bipolar Depression (BD) With Combination of Depakote ER (DEP) and Aripiprazole (AZP) |
| Lead sponsor | The University of Texas Health Science Center at San Antonio, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Bipolar Disorder |
| Intervention type | Drug |
| Interventions | Aripiprazole |
| Enrollment | 32 |
| Start date | Sep 1, 2004 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Sep 22, 2005 |
| Last update posted | May 16, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: